CareDx (CDNA) Q2 2026: EPS Beats by 59%, Revenue Tops $131M
As seen on the 24/7 Wall St. homepage on July 30, 2026.
CareDx demolished EPS expectations with a 59% beat and raised full-year guidance after Testing Services revenue surged 61% to $99.93 million, powered by accelerating molecular surveillance adoption and a strategic lab divestiture that swelled cash reserves to $373.6 million.
Continue ReadingShow less
CareDx reported Q2 2026 earnings per share of $0.37, well ahead of the $0.232 consensus estimate — a 59% beat that extended a strong run of outperformance. The company also cleared the revenue bar by a wide margin, posting $131.9 million against expectations of roughly $114 million, a 16% beat. Management followed the results by raising full-year guidance, signaling confidence that the momentum is sustainable.
The engine behind the quarter was Testing Services, where revenue surged 61% to $99.93 million. CareDx credited accelerating adoption of molecular surveillance — the use of advanced testing to monitor transplant patients for signs of organ rejection — as the primary driver. A strategic divestiture of a lab operation also reshaped the balance sheet, pushing cash reserves to $373.6 million and giving the company significant financial flexibility.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Looking at the recent earnings history, CareDx has now beaten EPS estimates in seven of the last eight quarters, and the magnitude of the beats has grown. The Q1 2026 result of $0.34 against a $0.13 estimate and the Q2 2026 outcome suggest analysts have consistently underestimated the pace of the company's turnaround. How durable the molecular surveillance tailwind proves to be, and how CareDx deploys its expanded cash position, are the key factors to watch in the quarters ahead.
Mentioned: CDNA